- Home
- DAWN vs XPEL Comparison
DAWN vs XPEL Comparison
Compare DAWN & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- XPEL
- Stock Information
- Founded
- DAWN 2018
- XPEL 1999
- Country
- DAWN United States
- XPEL United States
- Employees
- DAWN N/A
- XPEL 1054
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- DAWN Health Care
- XPEL Industrials
- Exchange
- DAWN Nasdaq
- XPEL Nasdaq
- Market Cap
- DAWN 1.3B
- XPEL 1.2B
- IPO Year
- DAWN 2021
- XPEL N/A
- Fundamental
- Price
- DAWN $12.24
- XPEL $43.36
- Analyst Decision
- DAWN Strong Buy
- XPEL Buy
- Analyst Count
- DAWN 7
- XPEL 2
- Target Price
- DAWN $36.33
- XPEL $49.00
- AVG Volume (30 Days)
- DAWN 1.1M
- XPEL 105.0K
- Earning Date
- DAWN 02-24-2025
- XPEL 02-20-2025
- Dividend Yield
- DAWN N/A
- XPEL N/A
- EPS Growth
- DAWN N/A
- XPEL N/A
- EPS
- DAWN N/A
- XPEL 1.75
- Revenue
- DAWN $101,953,000.00
- XPEL $418,411,000.00
- Revenue This Year
- DAWN N/A
- XPEL $8.08
- Revenue Next Year
- DAWN $35.22
- XPEL $13.97
- P/E Ratio
- DAWN N/A
- XPEL $24.78
- Revenue Growth
- DAWN N/A
- XPEL 13.32
- 52 Week Low
- DAWN $11.13
- XPEL $30.75
- 52 Week High
- DAWN $18.07
- XPEL $60.49
- Technical
- Relative Strength Index (RSI)
- DAWN 45.74
- XPEL 61.92
- Support Level
- DAWN $11.13
- XPEL $38.00
- Resistance Level
- DAWN $12.74
- XPEL $40.71
- Average True Range (ATR)
- DAWN 0.51
- XPEL 1.44
- MACD
- DAWN 0.06
- XPEL 0.55
- Stochastic Oscillator
- DAWN 51.15
- XPEL 90.24
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About XPEL XPEL Inc.
XPEL Inc is a provider of protective films and coatings, including automotive paint protection film, surface protection film, automotive and commercial/residential window films, and ceramic coatings. The company has a network of trained installers and proprietary DAP software, dedicated to exceeding customer expectations by providing quality products, customer service, technical support, and world-class training. The majority of revenue is derived from the United states.